News & Media / Opinions & Features

Theranos Debacle May Scare Investors Away From Diagnostic Technology

April 13, 2016

Now that Theranos faces the prospect of a crippling ban on its operations by federal officials, let’s get past its implosion and talk about the real implications for the rest of the diagnostic sector.

Continue Reading

Why Valeant Should Be Broken Up

March 17, 2016

It’s not often that we see the collapse of a large pharmaceutical company in real time.

Continue Reading

JPM 2016: Fear And Loathing In Healthcare From San Francisco

January 19, 2016

The gloom at the J.P. Morgan 34th annual healthcare conference in San Francisco last week is still thick in the air – and will likely to hover there for a while, as macro issues and falling investor confidence continue to cause problems for the U.S. pharmaceutical and biotech sector.

Continue Reading

How Mental Health is Shortchanged by Lack of Reimbursement for Vagus Nerve Stimulation

December 30, 2015

With a continuing weekly newsfeed on the destructive conse- quences of inadequate mental healthcare and with growing data on how depression negatively impacts the ability to perform daily tasks and engage in social interactions, why does a proven therapeutic intervention for chronic depression still remain far out of reach for so many patients?

Continue Reading

Shkreli Arrested: What Happened And What Happens Next?

December 17, 2015

The arrest of Martin Shkreli for securities fraud involving alleged misuses of funds from his former company, Retrophin Inc., raises more questions than it answers–and as the case plays out in federal court this gap will only increase.

Continue Reading

Diagnosing Theranos

December 5, 2015

It couldn’t have been easy for Elizabeth Holmes, CEO & founder of the controversial blood test company Theranos, to prepare for an interview with Matt Herper at the Forbes Healthcare Summit.

Continue Reading

The Pfizer/Allergan Merger May Be Dwarfed By The Merck/Express Scripts Divide

November 23, 2015

All eyes are fixed on the declared merger of Pfizer, Inc. and Allergan plc, which has the impact of an inversion, and the questions quickly become: Is it a game changer, a challenge to Treasury’s new tax inversion guidelines, or just riveting financial drama?

Continue Reading

The Truly Meaningful Ways To Honor Vets On Veterans Day

November 10, 2015

The history of holidays in the United States has been to turn religious, national, or social occasions into revenue opportunities.

Continue Reading

Ackman To The Rescue: Can He Make The Case For Valeant?

October 29, 2015

Valeant Pharmaceuticals is making headlines again as news continues to drip out on its business practices. Recently reports emerged that Valeant, a hedge fund darling, has the option right to acquire a private company called Philidor, a specialty pharmacy that provides it with distribution and marketing services.

Continue Reading

Will CVS And Walgreens Go The Way Of Blockbuster Or Netflix?

October 13, 2015

Insurance companies have a major stake in the national discussion on the cost of drugs. They’re usually pitted against big pharma and biotech, looking for ways to save money on care and drugs. One recent savings trend has been a push by major insurance companies to divert members from going to brick and mortar pharmacies like CVS Health Corporation (CVS) and Walgreens Boots Alliance , Inc. (WBA) and place them into mail-order pharmacies. By having drugs delivered to doorsteps instead of picked up at pharmacies, insurance companies can leverage their buying power and exercise even better control over what brands of drugs are utilized through a single, preferred distribution network. This could result in hundreds of millions of dollars in savings, cutting out countless middlemen who all play transactional roles in a fractured healthcare system. It could also tear the foundations of traditional brick and mortar pharmacies around the nation.

Continue Reading